-
Ribociclib and Acid-Reducing Agents: A QbD Study
2026-09-23
This study used a Quality by Design analytical method and biorelevant micro-dissolution experiments to examine pH-related changes in ribociclib succinate solubility. Although measured concentrations fell during simulated gastric-to-intestinal pH shifts, the authors judged the changes unlikely to indicate a substantial interaction with acid-reducing agents; clinical absorption was not directly tested.
-
Oligo (dT) 25 Beads: Practical mRNA Workflow
2026-09-23
Oligo (dT) 25 Beads provide a magnetic workflow for selectively capturing polyadenylated eukaryotic mRNA from total RNA or animal and plant cell and tissue samples. They are appropriate for mRNA enrichment and downstream cDNA, RT-PCR, library, and blotting workflows, but should not be treated as a general method for non-polyadenylated RNA or as a substitute for validated RNA integrity controls.
-
SDF-1beta (CXCL12) in Brucella Host-Cell Assays
2026-09-22
Explore how SDF-1beta (CXCL12), human recombinant can add a mechanistic chemokine-response layer to macrophage studies inspired by a genome-wide Brucella CRISPR screen. The article separates established findings from hypothesis-driven assay design and practical interpretation.
-
CDK9 inhibitor (A3294): Practical Lab Guide
2026-09-22
CDK9 inhibitor (A3294) provides a selective way to interrogate CDK9-dependent transcription elongation and HIV-1 propagation in biochemical and MT4 cell workflows. It should not be used as a pan-CDK reagent, a universal cytotoxicity probe, or a substitute for broad cell cycle regulation studies.
-
Phenothiazines, ROS, and Macrophage Antibacterial Defense
2026-09-21
Qiu et al. show that phenothiazines strengthen macrophage antibacterial activity through a linked increase in lysosomal activity, reactive oxygen species, and autophagy. Pharmacological inhibition of autophagy or ROS reduced this effect, while perphenazine improved lesion and inflammation outcomes in a Salmonella Typhimurium infection model, supporting phenothiazines as host-directed antibacterial lead compounds.
-
HyperScribe T7 High Yield Cy3 RNA Labeling Kit
2026-09-21
Generate tunable Cy3-labeled RNA probes for in situ hybridization and Northern blot workflows while balancing fluorescence against transcription yield. This guide connects practical probe synthesis with a cited nanocarrier study, showing how fluorescence can support delivery assays without confusing visualization with functional RNA interference.
-
Crizotinib hydrochloride in Gastric Cancer Assembloids
2026-09-20
Use Crizotinib hydrochloride to interrogate ALK, c-Met, and ROS1 signaling in patient-derived gastric cancer assembloids rather than relying on tumor-only cultures. This workflow pairs target-aware kinase inhibition with matched stromal models to expose microenvironment-dependent drug responses and resistance phenotypes.
-
Rotenone: Mitochondrial Complex I Workflows
2026-09-19
Rotenone is a controlled mitochondrial stressor for separating Complex I inhibition, ROS production, apoptosis, and autophagy responses in cell and animal studies. This workflow-focused guide connects established neurodegeneration applications with a cautious assay strategy inspired by new DPP9–KEAP1 redox biology.
-
JHU-083: A Redox-Aware Glutaminase Tool
2026-09-18
JHU-083 is a 6-diazo-5-oxo-L-norleucine precursor for selective glutaminase research in cerebral immune-cell models. This article explains how to pair its metabolic perturbation with redox-aware assays while avoiding unsupported conclusions from cross-tissue comparisons.
-
TP53 Mutations, FTH, and Ferroptosis in Glioblastoma
2026-09-18
A 2025 study identifies an iron-homeostasis vulnerability in TP53-mutant glioblastoma models: mutant TP53 increases ITCH-associated degradation of ferritin heavy chain, or FTH, raising intracellular free iron. This state can be tolerated under ferric ammonium citrate exposure but increases sensitivity to Erastin-driven ferroptosis, suggesting a genotype-informed strategy for studying ferroptotic stress in glioblastoma.
-
DPPH (2,2-Diphenyl-1-Picrylhydrazyl) Radical
2026-09-17
A practical, scenario-driven guide to using DPPH for in vitro antioxidant screening, extract comparison, and orthogonal support of cell-based research. It explains how SKU C3691 can improve assay planning through defined handling, solvent compatibility, fresh-solution preparation, and careful interpretation.
-
CFDA SE Cell Tracer Kit: Practical Protocol
2026-09-17
The CFDA SE Cell Tracer Kit provides stable fluorescent labeling for live-cell tracking, cell proliferation studies, and cell lineage tracing. It is intended for persistent covalent labeling over several days, not reversible or short-term staining workflows.
-
VX-765: Selective Caspase-1 Inhibition
2026-09-16
VX-765 is an orally absorbed caspase-1 prodrug that is converted to VRT-043198, its active metabolite. Evidence supports selective suppression of IL-1β and IL-18 release, caspase-1-dependent pyroptosis research, and preclinical inflammation studies, while BBB findings extend its use to neurovascular models.
-
Pyridostigmine, α7nAChR, and Placental Necroptosis
2026-09-16
A 2026 Biochemical Pharmacology study links enhanced non-neuronal cholinergic signaling with reduced placental necroptosis in a rat model of preeclampsia-like disease. Pharmacological blockade with α-bungarotoxin and rescue with necrostatin-1 provide evidence that α7nAChR-linked signaling may connect pyridostigmine exposure with lower inflammation, oxidative stress, and trophoblast dysfunction.
-
CENPI Drives Breast Cancer via Wnt/β-Catenin
2026-09-15
Wu and colleagues identify centromere protein I (CENPI) as an overexpressed breast cancer driver associated with progression and poor prognosis, and connect its activity to Wnt/β-catenin signaling. The study combines clinical datasets, cellular and xenograft models, RNA sequencing, protein analyses, and TOP/FOP reporter assays to establish a mechanistic framework for studying CENPI-dependent gene expression regulation.